Table 2. Antimicrobial resistance of ciprofloxacin-resistant Escherichia coli isolates for five major clones and each phylogenetic group.
| Antibiotics | Major clones | Phylogenetic groups | Total (%) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ST131 (%) | ST393 (%) | ST1193 (%) | ST38 (%) | ST405 (%) | A (%) | B1 (%) | B2 (%) | D (%) | ||
| FOF | 0/35 (0.0) | 0/18 (0.0) | 0/16 (0.0) | 0/11 (0.0) | 0/10 (0.0) | 0/4 (0.0) | 0/8 (0.0) | 0/59 (0.0) | 0/51 (0.0) | 0/122 (0.0) |
| FEP | 8/35 (22.9)a | 0/18 (0.0) | 1/16 (6.3) | 3/11 (27.3) | 1/10 (10.0) | 0/4 (0.0) | 0/8 (0.0) | 9/59 (15.3) | 6/51 (11.8) | 15/122 (12.3) |
| TMO | 3/35 (8.6) | 0/18 (0.0) | 1/16 (6.3) | 2/11 (18.2) | 1/10 (10.0) | 0/4 (0.0) | 0/8 (0.0) | 5/59 (8.5) | 5/51 (9.8) | 10/122 (8.2) |
| NIT | 0/35 (0.0) | 0/18 (0.0) | 0/16 (0.0) | 0/11 (0.0) | 0/10 (0.0) | 0/4 (0.0) | 0/8 (0.0) | 1/59 (1.7) | 0/51 (0.0) | 1/122 (0.1) |
| TMP/SMX | 17/35 (48.6) | 13/18 (72.2) | 10/16 (62.5) | 9/11 (81.8) | 8/10 (80.0) | 2/4 (50.0) | 5/8 (62.5) | 30/59 (50.8)b | 37/51 (72.5)b | 74/122 (60.7) |
| AMP | 28/32 (87.5) | 11/18 (61.1) | 11/16 (68.8) | 10/10 (100.0) | 10/10 (100.0) | 4/4 (100.0) | 5/7 (71.4) | 45/56 (80.4) | 39/50 (78.0) | 93/117 (79.5) |
| CTX | 12/30 (40.0) | 0/18 (0.0)a | 0/15 (0.0)a | 3/10 (30.0) | 6/9 (66.7)a | 1/4 (25.0) | 1/6 (16.7) | 15/56 (26.8) | 15/47 (31.9) | 32/113 (28.3) |
| CAZ | 12/30 (40.0) | 1/18 (5.6)a | 0/16 (0.0)a | 3/11 (27.3) | 6/10 (60.0) | 3/4 (75.0) | 1/7 (14.3) | 15/57 (26.3) | 16/51 (31.4) | 35/119 (29.4) |
| GEN | 20/33 (60.6) | 9/18 (50.0) | 3/16 (18.8)a | 11/11 (100.0)a | 4/10 (40.0) | 2/4 (50.0) | 2/7 (28.6) | 29/57 (50.9) | 31/51 (60.8) | 64/119 (53.8) |
| TOB | 21/32 (65.6) | 9/16 (56.3) | 3/16 (18.8)a | 8/10 (80.0) | 4/9 (44.4) | 2/4 (50.0) | 2/7 (28.6) | 30/56 (53.6) | 28/46 (60.9) | 62/113 (54.9) |
| AMK | 1/31 (3.2) | 0/12 (0.0) | 0/15 (0.0) | 0/10 (0.0) | 1/8 (12.5) | 0/4 (0.0) | 0/6 (0.0) | 1/53 (1.9) | 3/41 (7.3) | 4/104 (3.8) |
| ESBL production | 12/35 (34.3) | 1/18 (5.6)a | 0/16 (0.0)a | 3/11 (27.3) | 6/10 (60.0)a | 3/4 (75.0) | 1/8 (12.5) | 15/59 (25.4) | 16/51 (31.4) | 35/122 (28.7) |
| ESBL production + TMP/SMX resistance | 6/35 (17.1) | 1/18 (5.6) | 0/16 (0.0) | 3/11 (27.3) | 4/10 (40.0)a | 2/4 (50.0) | 1/8 (12.5) | 7/59 (11.9) | 10/51 (19.6) | 20/122 (16.4) |
FOF, fosfomycin; FEP, cefepime; TMO, temocillin; NIT, nitrofurantoin; TMP/SMX, trimethoprim-sulfamethoxazole; AMP, ampicillin; CTX, cefotaxime; CAZ, ceftazidime; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; ESBL, extended-spectrum beta-lactamase.
aP <0.05 and these relate to differences found when susceptibility profiles for isolates of each ST were compared with those all other STs combined.
bP <0.05 and these relate to differences found when susceptibility profiles for isolates of each phylogenetic group were compared with those all other phylogenetic groups combined.